PMC8349036_01
A: Increased uptake in the right triceps muscle (maximum standardized uptake value (SUV) = 6.3) in fluorodeoxyglucose positron emission tomography (FDG/PET) at the first visit. B: Computed tomography (CT) imaging taken at the first visit shows a nodule measuring 2.5 x 1.8 x 1.6 cm in the right triceps muscle. C: CT imaging taken just before starting nab-paclitaxel shows a mass measuring 2.7 x 4.0 x 5.4 cm in the right triceps muscle, D: CT imaging taken after two cycles of nab-paclitaxel shows a mass measuring 2.2 x 4.2 x 5.0 cm in the right triceps muscle. E: CT imaging taken six months after starting nab-paclitaxel shows a mass measuring 8.0 x 7.0 x 10.0 cm.
gr1.jpg
PMC8349036_01_gr1.jpg
fig1
A small nodule in his triceps brachii muscle had been recognized from computed tomography (CT) findings and showed increased radiotracer uptake on fluorodeoxyglucose positron emission tomography (FDG/PET)/CT scan (Fig. 1A and B). At this point, because the size of mass in his right upper arm had also increased, we suspected it was metastasis from his known NSCLC (Fig. 1B and C). After chemotherapy was changed to nab-paclitaxel, stable disease had been achieved (Fig. 1C and D). Whole-body CT scan demonstrated a large mass of 8.0 x 7.0 x 10.0 cm in his triceps brachii muscle involving low density (Fig. 1E).
Contrast-enhanced magnetic resonance imaging/T1-weighted image (A), T2-weighted images(B) after six months of starting nab-paclitaxel.
gr2.jpg
PMC8349036_01_gr2.jpg
fig2
Furthermore, contrast-enhanced magnetic resonance imaging (MRI) showed that the thick wall of the mass enhanced with gadolinium, and that the high signal of contents in the mass on the T2-weighted images and partially high signal on the T1-weighted images (Fig. 2).